Search results

From Self-sufficiency
Jump to: navigation, search

Page title matches

  • ...) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In additio
    3 KB (414 words) - 22:17, 21 September 2010
  • ...ture of [[celecoxib]], [[rofecoxib]] and other members of this drug class. COX-2 selectivity does not seem to reduce other [[adverse drug reaction|adverse e The COX-2 gene was discovered by UCLA scientist Dr. Harvey Herschman. [http://faculty
    30 KB (4,194 words) - 22:17, 21 September 2010

Page text matches

  • 54 KB (8,488 words) - 21:31, 2 July 2010
  • -Inhibition of gene transcription for COX-2, cytokines, cell adhesion molecules and inducible NO synthetase
    7 KB (872 words) - 16:41, 27 September 2010
  • 12 KB (1,557 words) - 16:44, 27 September 2010
  • ...nocarcinomas may be explained by its inhibition of [[Cyclooxygenase|PTGS2 (COX-2)]] enzymes expressed in them.<ref>{{Cite journal|author=Wolff, ''et al.''|t ===PTGS1 [COX-1] and PTGS2 [COX-2] inhibition===
    78 KB (10,918 words) - 16:52, 27 September 2010
  • ...and bleeding, selective [[COX-2 inhibitor]]s were developed to inhibit the COX-2 isoform without inhibition of COX-1.<ref name=emedicinepainmeds>{{Cite web|
    29 KB (3,955 words) - 22:17, 21 September 2010
  • 22 KB (2,916 words) - 16:50, 27 September 2010
  • 69 KB (10,077 words) - 21:35, 20 September 2010
  • ...ase]] (COX), and recent findings suggest that it is highly selective for [[COX-2]].<ref name="Hinz_2008">{{Cite pmid|17884974}}</ref> While it has [[analges Because of its selectivity for COX-2 it does not significantly inhibit the production of the pro-clotting [[thro
    54 KB (7,376 words) - 16:52, 27 September 2010
  • 17 KB (2,020 words) - 12:26, 7 July 2010
  • 1 KB (177 words) - 12:27, 7 July 2010
  • 1 KB (130 words) - 13:31, 19 September 2010
  • 1 KB (203 words) - 13:31, 19 September 2010
  • 61 KB (8,890 words) - 13:32, 19 September 2010
  • 12 KB (1,699 words) - 10:09, 20 September 2010
  • ...spholipase|phospholipase A2]] (PLA2), [[cyclooxygenase|cyclooxygenase-2]] (COX-2), and [[prostaglandin E2 synthase]]. These enzymes ultimately mediate the s
    27 KB (3,703 words) - 20:20, 20 September 2010
  • 33 KB (4,747 words) - 21:32, 20 September 2010
  • The effect of [[COX-2 selective inhibitor|COX-2 inhibitors]] such as [[rofecoxib]] and [[celecoxib]] upon the risk of colon
    94 KB (13,321 words) - 21:32, 20 September 2010
  • 22 KB (3,222 words) - 21:33, 20 September 2010
  • 4 KB (508 words) - 21:36, 20 September 2010
  • 45 KB (6,263 words) - 21:37, 20 September 2010
  • 67 KB (9,844 words) - 20:17, 21 September 2010
  • 177 KB (19,269 words) - 21:05, 21 September 2010
  • 71 KB (10,445 words) - 21:05, 21 September 2010
  • 39 KB (4,237 words) - 21:06, 21 September 2010
  • 43 KB (4,797 words) - 21:06, 21 September 2010
  • 37 KB (3,368 words) - 21:07, 21 September 2010
  • 7 KB (1,011 words) - 21:25, 21 September 2010
  • 13 KB (1,758 words) - 21:27, 21 September 2010
  • ...ted with prostaglandin-mediated side effects which have been reported with COX-2 inhibitors and NSAIDs, such as GI bleeding, renal insufficiency, cardiovasc
    796 bytes (102 words) - 22:04, 21 September 2010
  • ...tematic review of adverse renal and arrhythmia risk of valdcoxib and other COX-2 inhibitors, JAMA 2006] [[Category:COX-2 inhibitors]]
    6 KB (784 words) - 22:05, 21 September 2010
  • ===COX-2 inhibitors=== {{Main|COX-2 inhibitor}}
    14 KB (1,807 words) - 22:06, 21 September 2010
  • [[Category:COX-2 inhibitors]]
    841 bytes (99 words) - 22:07, 21 September 2010
  • 30 KB (4,151 words) - 22:14, 21 September 2010
  • 16 KB (2,012 words) - 22:15, 21 September 2010
  • ...intestinal side effects of NSAIDs like aspirin. In practice, use of some [[COX-2 inhibitor]]s with their [[Adverse drug reaction|adverse effects]] has led t ...he identification of increased risks of heart attacks with the selective [[COX-2 inhibitor]] [[rofecoxib]] in 2004, attention has focused on all the other m
    28 KB (3,886 words) - 22:16, 21 September 2010
  • ...NSAID properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis.
    5 KB (722 words) - 22:16, 21 September 2010
  • ...been shown, especially at its low therapeutic dose, selectively to inhibit COX-2 over COX-1.<ref name = noble>{{cite journal | last7 = Distel}}</ref> and perhaps all other NSAIDs which are not COX-2 selective.<ref name = hawkey>{{cite journal
    11 KB (1,540 words) - 22:16, 21 September 2010
  • ...hibit COX-1 and are designated as having "preferential selectivity" toward COX-2. Interestingly, the (inactive against COX) r-enantiomer of etodolac inhibit
    8 KB (1,051 words) - 22:16, 21 September 2010
  • ...i-inflammatory properties by inhibiting cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes reversibly, which decreases production of pro-inflammatory prostag
    11 KB (1,457 words) - 22:16, 21 September 2010
  • 3 KB (375 words) - 22:16, 21 September 2010
  • ...) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In additio
    3 KB (414 words) - 22:17, 21 September 2010
  • ...ture of [[celecoxib]], [[rofecoxib]] and other members of this drug class. COX-2 selectivity does not seem to reduce other [[adverse drug reaction|adverse e The COX-2 gene was discovered by UCLA scientist Dr. Harvey Herschman. [http://faculty
    30 KB (4,194 words) - 22:17, 21 September 2010
  • 4 KB (444 words) - 22:17, 21 September 2010
  • ...(COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) [[isoenzyme]]s. COX catalyzes the formation of [[prostaglandin]]s and [[th ===Selective COX-2 inhibitors (Coxibs)===
    35 KB (4,649 words) - 22:18, 21 September 2010
  • 32 KB (4,462 words) - 21:01, 24 September 2010
  • 21 KB (2,875 words) - 21:03, 24 September 2010
  • 73 KB (10,437 words) - 14:50, 10 December 2011
  • 6 KB (816 words) - 14:51, 10 December 2011